About CLINUVEL

Tuesday, 29 January 2013 19:37

JAMA features vitiligo study as cover story

In October 2012 we announced that observations from the CUV102 study of SCENESSE® (afamelanotide 16mg implant) in vitiligo were e-published in the journal Archives of Dermatology. Earlier this month the article was fully published in the re-named JAMA Dermatology, with case study images from CUV102 featured on the cover. You can access the abstract to this article at the JAMA's website.

Reference:

Grimes PE, et al (2013). "The Efficacy of Afamelanotide and Narrowband UV-B Phototherapy for Repigmentation of Vitiligo" JAMA Dermatol. 149(1):68-73.

Latest Company Announcements

07 December 2017

CLINUVEL Newsletter - December 2017

The CLINUVEL team is looking with much optimism and energy to the start of 2018.

Read More
05 December 2017

Lapse and Forfeit of Unlisted Conditional Performance Rights

Lapse and Forfeit of Unlisted Conditional Performance Rights

Read More
05 December 2017

Appendix 3Z - Final Director’s Interest Notice

Final Director’s Interest Notice

Read More
27 November 2017

Chair's Address to the Annual General Meeting

Coming from the background of an ethical pharmaceutical company I had some misgivings 15 years ago of joining the board of a company with a ‘tanning’ drug.

Read More
27 November 2017

Managing Director's AGM Presentation

AGM Presentation

Read More
27 November 2017

Results of Meeting

AGM results

Read More

Quick Links